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Abstract
Introduction: Loss of the retinoblastoma protein tumor suppressor gene (RB) coding for a nuclear phosphoprotein
that regulates the cell cycle is found in many human cancers and probably leads to disruption of the p16-cyclin
D1-CDK4/6-RB pathway. Cyclin D1 is known to activate CDK4, which then phosphorylates the RB protein, leading
to cell cycle progression. p16 inhibits CDK4, keeping RB hypophosphorylated and preventing cell cycle progression.
The significance of these three markers, cyclin D1, CDK4 and p16, for breast cancer and carcinogenesis is
nevertheless still controversial.
Methods: The material consisted of 102 formalin-fixed human breast cancer samples, in which cyclin D1, CDK4
and p16 expression was evaluated immunohistochemically. The amounts of cyclin D1 mRNA present were
analyzed by quantitative real time PCR.
Results: High cyclin D1 expression statistically significantly correlated with lower tumor grade, estrogen and
progesterone receptor positivity and lower proliferation activity in breast tumors and increased breast cancer-
specific survival and overall survival. Tumors with high cyclin D1 protein had 1.8 times higher expression of cyclin
D1 mRNA. CDK4 expression did not correlate with cyclin D1 expression or the survival data. p16 expression was
associated with Human Epidermal Growth Factor Receptor 2 (HER2) negativity and increased breast cancer-specific
survival and disease-free survival. No statistical correlations between cyclin D1, CDK4 and p16 were found.
Conclusions: Cyclin D1 was associated with a good breast cancer prognosis but functioned independently of
CDK4. High cyclin D1 expression may be partially due to increased CCND1 transcription. p16 correlated with a
better prognosis and may function without CDK4. In conclusion, it appears that cyclin D1, CDK4 and p16 function
independently in human breast cancer.
Introduction
The retinoblastoma tumor suppressor gene (RB) encodes
a nuclear phosphoprotein that plays a central role in reg-
ulating the cell cycle [1]. RB regulates progression
through the G1-to-S phase transition of the cell cycle [1].
Loss of RB is well documented in many human tumor
types and it is probable that the p16-cyclin D1-CDK4/6-
RB pathway is disrupted in most human malignancies
[2]. Extracellular signals induce the expression of cyclin
D1 in cells entering the cell cycle and this binds to and
activates cyclin-dependent kinases (CDK4 and CDK6)
(Figure 1) [1-5]. The ensuing complexes in turn lead to
the phosphorylation of RB, resulting in its dissociation
from the transcription factors, predominantly members
of the E2F family, which then activate the many genes
required for progression of the cell cycle to the S phase
(Figure 1) [1-3]. p16, also known as p16INK4a, a member
of the INK4 family of CDK inhibitors, inhibits CDK4 and
CDK6, maintaining RB in its hypophosphorylated E2F-
associated state, and thereby preventing G1-to-S phase
progression (Figure 1) [6,7]. Inactivation of p16 results in
a loss of the inhibition of RB phosphorylation, facilitating
a loss of control over cell cycle arrest [2]. In the case of
breast tumors there may be genetic events upstream of
RB which can negatively affect RB function by promoting
its phosphorylation. These may include p16 loss [5] and
CCND1 amplification or Cyclin D1 overexpression [8].
CDK4 activity is deregulated in many human tumors [9].
It has been shown that CDK4 and CDK6 are dispensable
when it comes to driving the essential cell cycle, but they
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are required in specialized tissues and possibly for achiev-
ing higher levels of proliferation [10,11]. CDK4 has been
shown to be absolutely crucial for various oncogenic trans-
formation processes, suggesting that many cancer cells
may be addicted to high CDK4 activity [9].
Cyclin D1 is a product of the CCND1 gene [12], which is
today considered a well-established human oncogene [5].
The gene and its product have been extensively examined
in cases of cancer and there is significant evidence of their
involvement in breast, lung, colon, bladder and liver can-
cers, melanoma, oral squamous cell carcinomas and man-
tle cell lymphoma [4,5,13]. The amplification of CCND1
and the overexpression of the cyclin D1 protein frequently
occur in breast cancer, although overexpression of the
protein is not always due to gene amplification [4,5].
Estrogen uses cyclin D1 as one of its target genes to med-
iate its mitogenic effects [12]. Cyclin D1 expression has
been shown in previous human breast cancer studies to
correlate with positive ER status [12,14], the protein being
predominantly expressed in the well-differentiated, low-
grade, slow-growing subtypes of breast cancer [12].
The product of the CDKN2 gene, p16, acts as a tumor
suppressor [15], while inactivation of the gene has been
found to be a common event in nearly half of all human
cancers studied [16]. Normal proliferating cells do not
express significant levels of p16 prior to extensive rounds
of cell division, which may suggest a late-stage antiproli-
ferative role for p16, as in the senescence of replicative
cells [17]. The activation of p16 expression can be trig-
gered by DNA damage, oncogenic stress or physiological
aging [7]. The significance of p16 overexpression is not
fully understood, however, and it has been associated with
both better and poorer prognosis of cancer. p16 has been
associated with a poor prognosis for neuroblastoma and
cervical, ovarian, breast and prostate tumors [6]. Recent
studies have shown a correlation between overexpression
of p16 and both an infiltrative tumor border pattern in
breast cancer [16] and the basal-like phenotype [18-19].
In the present work, we assessed the expression of
cyclin D1, CDK4 and p16 in human invasive ductal
mammary carcinoma samples, correlated the findings











Figure 1 Regulation of the cell cycle G1/S transition by cyclin D1, CDK4 and p16. RB, retinoblastoma protein, CDK4/6, cyclin-dependent
kinase 4/6.
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investigated the correlations of these three markers with
survival functions. As has been said, all the factors stu-
died here contribute to the RB pathway, and the aim was
to reveal the significance of cyclin D1 and its regulators,
CDK4 and p16, and their interrelations in human breast
cancer.
Methods
Patient and tumor material
The series consisted of 102 formalin-fixed, paraffin-
embedded tumor specimens from female breast cancer
patients from the archives of the Department of Pathology,
Oulu University Hospital, Finland, dating from the years
2000 to 2007. Informed consents were obtained from the
patients. The approval of the local Ethical Committee and
the Finnish National Supervisory Authority for Welfare
and Health was obtained for the use of the tumor speci-
mens and patient medical records. Information regarding
patient characteristics was obtained from the clinical and
pathological records. The diagnoses were re-evaluated by
the pathologist according to the WHO classification [20]
in the course of grading the immunohistochemical stain-
ings. The TNM classification classes T1 to T4 were used
to evaluate the tumor size (T1: ≤ 2 cm, T2: > 2 cm but ≤ 5
cm, T3: > 5 cm and T4: tumor of any size, with direct
extension to chest wall or skin. The clinical characteristics
of the patients are summarized in Table 1.
Immunohistochemistry (IHC) and scoring
Tissue processing
The surgical specimens were placed in formalin prior to
embedding in paraffin for subsequent routine light micro-
scopy and immunohistochemical analysis of cyclin D1,
CDK4 and p16. The immunostaining was carried out as
follows. Three micrometer sections were deparaffinized
and treated with TRIS/EDTA with pronase for epitope
retrieval. After this the sections were incubated with
blocking solution (EnVision Detection System, Dako,
Glostrup, Denmark) to block nonspecific binding of IgGs
and then incubated with polyclonal antibodies to cyclin
D1, diluted 1:25 (M3635, Dako North America Inc., Car-
pinteria, CA, USA), CDK4, diluted 1:100 (DCS-35: sc-
23896, Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA), and p16, non-diluted (CINtec, mtm Laboratories
AG, Heidelberg, Germany). The color was developed with
diaminobenzidine tetrahydrochloride (DAB) (EnVision
Detection System, Dako). All the steps were followed by
washes with tween/phosphate-buffered saline (PBS).
Finally, the sections were lightly counterstained with
hematoxylin before analysis by light microscopy and scor-
ing as for DAB staining. For negative controls, the sections
were incubated with PBS instead of the primary antibo-
dies. Immunohistochemical analysis of the expression of
PHD1-3, HIF-1a and HIF-2a in the same cohort has been
described before [21].
Scoring
The cytoplasmic and nuclear stainings were evaluated indi-
vidually for all three markers, and the intensities of both
were scored on a scale from 0 to 3, where 0 = negative, 1 =
week, 2 = moderate, and 3 = strong staining. Also, the per-
centage of nuclei was assessed in each case and scored on
a scale of 0 to 100%. Evaluation of the staining of PHD1-3,
HIF-1a and HIF-2a has been described before [21].
The cut-off points for Ki-67 were: negative < 5%, + 5 to
15%, ++ 16 to 30%, and +++ > 30%. Human Epidermal
Table 1 Patient characteristics
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Growth Factor Receptor 2 (HER2) was considered posi-
tive in IHC when the result was either ++ or +++
(reflecting moderate to strong intensity in all or almost
all tumor cells), and gene amplification status was deter-
mined using chromogenic in situ hybridization. Cancers
with six or more gene copies were considered HER2
positive [22].
The cut-off value for estrogen and progesterone recep-
tors (ER and PR respectively) was 10%. Tumor samples
with ER or PR expression less than 10% were considered
negative and the others positive.
RNA extraction, cDNA synthesis and quantitative real
time PCR (Q-PCR)
RNA was extracted from the paraffin sections of breast
tumors with NucleoSpin FFPE RNA/DNA (Macherey-
Nagel, Düren, Germany). A total of 100 ng of RNA was
used for cDNA synthesis performed with iScript (Bio-Rad,
Hercules, CA, USA). The amount of cyclin D1 mRNA
relative to 18S rRNA in the samples was analyzed by
Q-PCR performed in a Stratagene MX3005 thermocycler
with iTaq SYBR Green Supermix and ROX (Bio-Rad) and
the primers qHs3CCND1For 5’-GCTCCTGGTGAACA
AGCTCAA-3’, qHs3CCND1Rev 5’-TTGGAGAGGAAG
TGTTCAATGAAA-3’, Hs18SFor 5’-GACTCAACACGGG
AAACCTC-3’ and Hs18SRev 5’-AGCATGCCAGAGT
CTCGTTC-3’, respectively.
Statistical analyses
The statistical analyses were carried out with SPSS 17.0
(SPSS Inc., Chicago IL, USA). The clinical characteristics
were expressed as percentages. The Chi-square test or
Fisher’s exact test was used to evaluate the associations
and correlations, as appropriate. A two-tailed P-value was
used in all the analyses, and a P-value < 0.05 was consid-
ered statistically significant. Disease-free survival, breast
cancer-specific survival and overall survival were analyzed
by the Kaplan-Meier method using Cox regression.
Hazard ratios (HR) and 95.0% confidence intervals (95.0%
CI) are indicated. Disease free survival was considered as
the primary endpoint.
For the statistical analyses, the staining results for the
proteins studied were combined to form a positive and a
negative group. Cyclin D1 was considered positive when
the proportion of stained nuclei was > 40% and when the
intensity of the nuclear staining was strong and negative
in other cases. CDK4 and p16 were scored as negative
when ≤ 2% of the nuclei were stained and the nuclear
intensity was negative or weak and as positive in other
cases.
Results
All the 102 patients were women and their median age
was 59 years (range 28 to 87 years). The prognostic factors
are described in Table 1. The majority of the tumors were
of low tumor stage (64.7% were T1), nodal negative
(56.9%), and steroid receptor positive (76.5% were ER posi-
tive and 65.7% PR positive). A total of 17.6% of the tumors
were HER2 positive. Grades I to III were represented in
almost equal numbers. About 40% of the cancers were
intermediate or highly proliferated. The adjuvant treat-
ments provided for the patients are described in Table 1.
Only 12% of the patients did not receive any adjuvant
therapy (Table 1).
The purpose here was to correlate the immunohisto-
chemical expression of cyclin D1, CDK4 and p16 with
the main clinical prognostic factors for breast cancer:
tumor stage, nodal status, tumor grade, steroid receptors
(ER and PR), HER2 status and proliferation rate.
Cyclin D1 showed nuclear and cytoplasmic staining
(Figure 2A, B), and CDK4 only nuclear staining (Figure
2C, D), while p16 staining was mainly detected in the
nuclei and to a lesser extent in the cytoplasm (Figure 2E,
F). It is also significant that the presence of lymphocyte
nuclei always meant positivity for cyclin D1 and that of
fibroblasts often for p16 (data not shown).
About 60% of the stained specimens showed nuclear
cyclin D1 expression. Statistically significant correlations
emerged between cyclin D1 and a lower tumor grade (P =
0.013), ER and PR positivity (P = 0.000, P = 0.024, respec-
tively) and a negative or low proliferation rate (P = 0.031)
(Table 2). Likewise, cyclin D1 expression was shown to
correlate with increased breast cancer-specific survival
(P = 0.020; HR = 4.26; 95.0% CI = 1.12, 16.1) (Figure 3A)
and increased overall survival (P = 0.013; HR = 3.93; 95.0%
CI = 1.23, 12.6) (Figure 3B), but it had no significant asso-
ciation with disease-free survival (data not shown).
Evaluation of the relation of cyclin D1 protein expres-
sion in the histological sections to cyclin D1 mRNA in
the corresponding tumor samples by means of Q-PCR
showed that tumors with high cyclin D1 protein had 1.8
times higher expression of cyclin D1 mRNA than those
with low or negative cyclin D1 in the histological sections
(Figure 4), suggesting that the higher cyclin D1 protein
level is at least partially due to increased expression of
CCND1.
Although about 70% of the tumor samples showed
nuclear CDK4 expression, no statistically significant corre-
lation was found between this and any of the clinico-
pathological factors studied (Table 2). There was, however,
a tendency for CDK4 expression to correlate with a high
tumor grade (P = 0.156) (Table 2), but not with any of the
survival functions (data not shown).
Nuclear p16 expression was seen in 55% of the breast
carcinoma specimens. It correlated significantly only with
HER2 negativity (P = 0.022). In addition, we found a sta-
tistically significant correlation between p16 expression
and increased breast cancer-specific survival (P = 0.028;
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HR = 4.0; 95.0% CI = 1.0, 15.0) (Figure 5A) and increased
disease-free survival (P = 0.004; HR = 4.1; 95.0% CI = 1.5,
12.0) (Figure 5B), but not with overall survival (data not
shown).
The interrelations between the above three markers
were analyzed, as they are linked together in the cell cycle,
but no statistically significant correlation was found
between cyclin D1 and CDK4 or between CDK4 and p16.
There was a trend for a positive correlation between cyclin
D1 and p16, however (P = 0.145). No significant correla-
tion among all three factors was observed in a three-vari-
able logistic regression model.
When we considered the relations between the expres-
sion of cyclin D1, CDK4 and p16 and hypoxia-inducible
factor (HIF) prolyl 4-hydroxylases PHD1, 2 and 3, HIF-1a
and HIF-2a, the expression of which we had studied ear-
lier in the same samples [21], we found positive correla-
tions between p16 and both PHD1 (P = 0.032) and PHD2

Figure 2 Cyclin D1, CDK4 and p16 expression in invasive ductal breast carcinomas analyzed by immunohistochemistry . (B) High
nuclear cyclin D1 expression. (D) High nuclear CDK4 expression. (F) High p16 expression. (A), (C) and (E) are negative controls for (B), (D) and
(F), respectively.
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(P = 0.027) and a correlation between CDK4 positivity and
PHD3 negativity (P = 0.031).
Discussion
Disruption of the p16-cyclin D1-CDK4/6-RB pathway
occurs frequently in many human cancers [2], and we
investigated here the expression profiles of three distinct
factors involved in this pathway: cyclin D1, CKD4 and
p16. Overexpression of cyclin D1 has earlier been asso-
ciated with breast cancer subtypes that are more indo-
lent, estrogen receptor positive, and have a better
prognosis [12], and our findings pointed to a similar pat-
tern. Cyclin D1 was statistically significantly correlated
with estrogen and progesterone receptor positivity, a
lower tumor grade and lower proliferation activity, that
is, with breast cancers that have a good prognosis.
In addition, high cyclin D1 expression significantly
increased breast cancer-specific survival and overall sur-
vival in our cohort. Gene amplification of CCND1 has
been reported to be associated with an increased risk of
breast cancer recurrence, while nuclear expression of
cyclin D1 protein was associated with a decreased recur-
rence rate [23]. Amplification of the CCND1 gene has
been identified in approximately 15 to 20% of human
breast cancers, while overexpression of cyclin D1 protein
has been demonstrated in 50 to 70% [5]. Our data
showed a correlation between a high cyclin D1 mRNA
level and high cyclin D1 protein expression. Hence, at
least some of the increased protein expression of cyclin
D1, if not all, must be due to the amplification of the
Table 2 Cyclin D1, CDK4 and p16 expression in breast cancer in relation to clinicopathological variables
Cyclin D1 - n (%) Cyclin D1 + n (%) P-value Cdk4 - n (%) Cdk4 + n (%) P-value P16 - n (%) p16 + n (%) P-value
Tumour
T1 21 (52.5) 41 (73.2) 14 (56.0) 39 (65.0) 27 (64.3) 32 (62.7)
T2 13 (32.5) 12 (21.4) 10 (40.0) 14 (23.4) 10 (23.8) 15 (29.4)
T3 3 (7.5) 3 (5.4) 1 (4.0) 5 (8.3) 2 (4.8) 4 (7.8)
T4 3 (7.5) 0 (0.0) 0 (0.0) 2 (3.3) 3 (7.1) 0 (0.0)
0.066 0.431 0.273
Nodus
Negative 20 (51.3) 34 (61.8) 15 (65.2) 34 (56.7) 26 (61.9) 29 (59.2)
Positive 19 (48.7) 21 (38.2) 8 (34.8) 26 (43.3) 16 (38.1) 20 (40.8)
0.309 0.478 0.791
Grade
I 9 (22.5) 20 (35.7) 11 (44.0) 14 (23.3) 11 (26.2) 17 (33.3)
II 10 (25.0) 23 (41.1) 6 (24.0) 22 (36.7) 14 (33.3) 16 (31.4)




Negative 18 (45.0) 3 (5.4) 6 (24.0) 14 (23.3) 10 (23.8) 12 (23.5)




Negative 18 (45.0) 13 (23.3) 8 (32.0) 22 (36.7) 15 (35.7) 18 (35.3)
Positive 22 (55.00) 43 (76.8) 17 (68.0) 38 (63.3) 27 (64.3) 33 (64.7)
0.024* 0.682 0.966
HER2
Negative 30 (75.0) 48 (85.7) 21 (84.0) 48 (80.0) 28 (66.7) 47 (92.2)
Positive 10 (25.0) 8 (14.3) 4 (16.0) 12 (20.0) 14 (33.3) 4 (7.8)
0.185 0.769 0.002**
Ki67
Negative 8 (20.0) 12 (21.4) 6 (24.0) 9 (15.0) 8 (19.0) 10 (19.6)
+ 10 (25.0) 24 (42.9) 11 (44.0) 21 (35.0) 15 (35.7) 18 (35.3)
++ 7 (17.5) 13 (23.2) 2 (8.0) 16 (26.7) 10 (23.8) 9 (17.6)
+++ 15 (37.5) 7 (12.5) 6 (24.0) 14 (23.3) 9 (21.4) 14 (27.5)
0.031* 0.251 0.856
* P < 0.05, ** P < 0.01, *** P < 0.001.
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corresponding gene. The prognostic significance of cyclin
D1 overexpression with respect to cancer in general does
not seem to be consistent, however. High expression of
cyclin D1 has been associated with resistance to tamoxifen
therapy [24-26]. And in another hormone-dependent can-
cer type, prostate cancer, overexpression of cyclin D1 is
associated with a high proliferative index and a metastatic
disease, and it has been suggested that high cyclin D1 may
be related to the evolution of an androgen-independent
disease form [27].
Although CDK4 was expressed in about 70% of our
tumor samples, it surprisingly did not show any significant
correlations with the main clinical prognostic factors for
breast cancer nor with the survival functions. A tendency
for CKD4 positivity to correlate with a higher tumor grade
was noticed, however, coinciding with the notion that
CDK4 promotes tumor cell proliferation [10]. This is not
entirely surprising since others have reported earlier in a
similar size German cohort that even though 16% of
sporadic breast cancers overexpressed CDK4, no associa-
tion between any of other clinical factors, except Ki-67,
was observed [28]. It is thought that the ability of cyclin
D1 to activate CDK4 is critical for driving tumorigenesis,
and that CDK4-associated kinase activity is required to
maintain this tumorigenesis, as shown in mice with Her2-
induced, but not Wnt-1-induced [29] and Ras-induced
breast cancer [30]. However, we did not find any correla-
tion between CDK4 and cyclin D1 expression. It has, how-
ever, been reported that the oncogenic activity of cyclin
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Figure 3 Kaplan-Meier curves for breast cancer-specific and overall survival stratified by cyclin D1 expression. (A) Breast cancer-specific
survival of patients with high tumor cyclin D1 expression relative to negative or low expression (P = 0.020). (B) Overall survival of patients with




















Figure 4 Relative expression of cyclin D1 mRNA to cyclin D1
protein in breast carcinoma specimens. Expression of cyclin D1
mRNA was studied relative to 18S rRNA (CCND1/18S). High and low
cyclin D1 indicate the expression levels of the protein.
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only does the interaction between CDK4/6 and cyclin D1
suggest that they act interdependently, but cyclin D1 has
also been reported to function independently of CDK4/6
in supporting proliferation by directly activating estrogen
receptors [12]. As noted previously, our data point to a
high correlation between positive ER status and cyclin D1
expression, which supports the suggestion of a direct
estrogen receptor-mediated mode of function for cyclin
D1. Collectively, these data together with some previous
data [28] suggest that the role of CDK4 in human breast
carcinogenesis differs from that in mouse and further
emphasizes the importance of clinical studies.
As a tumor suppressor, p16 is a negative cell cycle regu-
lator, and its inactivation appears to be a common event in
many cancers [16], and in many cases it is associated with
poorer prognosis. For example, p16 overexpression has
been found in high-grade carcinomas of the oropharynx
and the genital and genitourinary tracts [32-34]. Yet the
role of its overexpression in human breast cancer is a point
of controversy. We found a significant correlation between
high p16 expression and HER2 negativity, and expression
of the oncogene HER2 is considered a very poor prognostic
factor for breast cancer [35]. An association of ER negativ-
ity, higher grading and high proliferation activity with the
overexpression of 16 has been detected in previous breast
cancer studies [36], as also has its association with the
basal-like phenotype [18,19]. However, in our cohort, sta-
tistically significant correlations between high p16 expres-
sion and both increased disease-free survival and increased
breast cancer-specific survival were observed.
The expression of p16 has been shown to correlate with
the inhibition of VEGF and angiogenesis, but the mechan-
ism by which p16 regulates VEGF has not been properly
explored. One hypothesis is that the activity of HIF-1a,
which is responsible for hypoxia-induced malignant pro-
gression, including VEGF transactivation, can be attenu-
ated by p16 [37]. Moreover, p16 itself has been shown to
be hypoxia-inducible [38]. On the other hand, we did not
find any correlation between p16 and HIF-1a or HIF-2a,
having studied the expression of both of these in the same
cohort earlier [21]. The HIF prolyl 4-hydroxylases, PHD1-
3, are oxygen sensors that negatively regulate HIF-a [39].
In the present work, p16 had a positive correlation with
PHD1 and PHD2, while CDK4 had an inverse correlation
with PHD3. The levels of expression of PHD1-3 have been
determined in the same set of samples earlier [21], and
similarly to high p16 expression, high PHD2 expression
had a tendency to promote breast cancer-specific survival
and disease-free survival [21]. The most significant corre-
lation found earlier for PHD3 was with a low tumor grade
(P = 0.000) [21], while interestingly, there was a tendency
for high CDK4 expression to correlate with a high tumor
grade, supporting the identified inverse relation between
these factors. PHD3 depletion under hypoxia has been
shown in a recent study involving a head and neck squa-
mous cell carcinoma line to be associated with cell cycle
arrest at the G1/S interface, in that it reduces the amount
of hyperphosphorylated RB [40].
To our knowledge, this is the first time when the interre-
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Figure 5 Kaplan-Meier curves for breast cancer-specific and disease-free survival stratified by p16 expression. (A) Breast cancer-specific
survival of patients with high tumor p16 expression relative to negative or low expression (P = 0.028). (B) Disease-free survival of patients with
high tumor p16 expression relative to negative or low expression (P = 0.004).
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in human breast cancer patient samples. We show in this
cohort that the expression of two of the studied markers,
p16 and cyclin D1, correlates with better prognosis of
breast cancer. A significant association of these factors in
the rather small cohort with limited number of events
highlights the strength of these findings. Our data on cyclin
D1 and CDK4 agree with those in some earlier patient stu-
dies [12,14,28]. The failure to identify an interrelation
among cyclin D1, CDK4 and p16 may be due to a limited
cohort size, or a more complex interrelation beyond the
protein level expressions studied here.
Conclusions
In summary, high p16 expression correlated with HER2
negativity and longer breast cancer-specific and disease-
free survival in human breast cancer. In addition, our data
confirm earlier findings correlating high cyclin D1 expres-
sion with a good prognosis for breast cancer. The expres-
sion levels of cyclin D1 protein and mRNA correlated with
each other. Surprisingly, no significant correlations among
cyclin D1, CDK4 and p16 were found in terms of their
expression.
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